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Abstract 
We previously demonstrated that CD4
+CD25
+ T regulatory cells (Tregs), important 
for the maintenance of immune tolerance and prevention of autoimmune disease, from 
patients with human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) exhibit reduced Foxp3 expression and Treg suppressor 
function compared to normal donors.  Since TGF-β signaling has been previously reported 
to be critical for both Foxp3 expression and Treg function, we examined whether this 
signaling pathway was dysregulated in patients with HAM/TSP.  Levels of TGF-β receptor 
II (TGF-βRII) as well as Smad7 (a TGF-β-inducible gene) were significantly reduced in 
CD4
+ T cells in patients with HAM/TSP compared to normal donors, and the expression of 
TGF-βRII inversely correlated with the HTLV-I tax proviral load.  Importantly, both 
CD4
+CD25
+ and CD4
+CD25
- T cells from HAM/TSP patients exhibited reduced TGF-βRII 
expression compared to normal donors, which was associated with functional deficits in 
vitro, including a block in TGF-β-inducible Foxp3 expression that inversely correlated with 
the HTLV-I tax proviral load, loss of Treg suppressor function and escape of effector T 
cells from Treg-mediated control.  This evidence suggests that a virus-induced breakdown 
of immune tolerance affecting both regulatory and effector T cells contributes to the 
pathogenesis of HAM/TSP. 
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INTRODUCTION 
HTLV-I is an exogenous retrovirus that has been estimated to infect between 15 and 
20 million people worldwide 
1.  While most infected individuals remain life-long 
asymptomatic carriers of the virus, a small percentage progress and develop either an 
aggressive T cell leukemia known as adult T cell leukemia (ATL) or a chronic 
inflammatory disorder of the central nervous system (CNS) known as HTLV-I-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) 
2-5.  HAM/TSP is characterized as a 
chronic progressive myelopathy with involvement principally in the spinal cord 
6.  CNS 
white matter lesions of the spinal cord have been reported to harbour activated CD4
+ and 
CD8
+ T cells during early stages of disease, with a predominance of CD8
+ T cells later in 
disease 
7.  HTLV-I viral RNA has been found associated with CD4
+ T cells and astrocytes 
in CNS lesions 
8-12, suggesting that virus-infected cells can migrate through the blood-brain 
barrier and infect CNS resident cells 
13.  Elevated levels of proinflammatory cytokines IL-6, 
IFN-γ, and IL-12 have been detected in the serum and CSF of patients with HAM/TSP 
compared to healthy controls 
14,15 and virus-specific CD8
+ T cells from HAM/TSP patients 
exhibit a predominantly effector/memory phenotype 
16.  IL-1β, TNF-α, and IFN-γ have also 
been detected in inflammatory lesions during early stages of disease 
17.  While the 
mechanisms underlying disease pathogenesis remain unresolved the above evidence 
strongly suggests that both viral gene expression (in particular the expression of the viral 
transactivating gene tax) and the host immune response are involved in the pathogenesis of 
this disease.  With respect to viral gene expression, the HTLV-I tax proviral load has been 
found to directly correlate with both Tax mRNA levels and the frequency of Tax-specific 
CD8
+ T cells in PBMCs from HAM/TSP patients 
16,18.  It has therefore been suggested that 
the HTLV-I tax proviral load determines (along with cellular signaling) the level of viral 
gene expression, which in turn triggers a strong virus-specific CD8
+ (as well as CD4
+) T 
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cell response, leading to CNS inflammation, myelin loss, and axonal damage through direct 
killing of infected cells in the CNS, bystander-mediated cytotoxicity, and/or molecular 
mimicry. 
While HTLV-I has been reported to infect a number of cell types in vitro and in vivo 
12,19,20, we have previously demonstrated using molecular and immunological techniques 
that the predominant viral reservoir in the peripheral blood is CD4
+CD25
+ T cells 
21.  In 
healthy individuals, CD4
+CD25
+ T cells that are hyporesponsive to antigenic stimulation 
and are capable of suppressing the proliferation and cytokine production of CD4
+CD25
- 
and CD8
+ effector T cells (Teffs) in vitro are defined as regulatory T cells (Tregs) 
(reviewed in 
22).  Pandiyan and colleagues have recently described that CD4
+CD25
+ T cells 
may also function to control inflammation through cytokine deprivation-induced apoptosis 
of effector T cells (Teffs) 
23. Although phenotypically similar to activated T cells, Tregs can 
be identified ex vivo by the intracellular expression of the transcriptional regulator Foxp3 
24.  Foxp3 is critical for the development and function of Tregs in both mice and humans, as 
genetic mutation of the Foxp3 gene has been found to be responsible for the severe multi-
focal lymphoproliferative autoimmune phenotype of the scurfy mouse and immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) in humans 
25.  
Previous studies have observed significant reductions in Foxp3 expression and/or Treg 
function in several human autoimmune diseases, including multiple sclerosis (MS), 
myasthenia gravis, and type I diabetes 
26-28, suggesting that defects in Foxp3 expression 
and/or Treg function may precipitate loss of immunological tolerance.  Recently, we have 
reported that CD4
+CD25
+ T cells from patients with HAM/TSP had reduced levels of 
Foxp3 mRNA and protein compared to healthy individuals, and that this reduction was 
associated with a loss of suppressor function 
29.  This observation suggested that a defective 
Treg compartment may account for, at least in part, the persistent virus-specific cellular and 
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humoral immune response observed in HAM/TSP patients.  Although overexpression of a 
single HTLV-I gene (tax) was capable of reducing Foxp3 expression and dampening the 
suppressive function of normal donor CD4
+CD25
+ T cells, the mechanisms underlying 
these events remain unresolved. 
TGF-β is a potent anti-inflammatory cytokine capable of suppressing T cell 
proliferation and modulating T cell differentiation 
30.  A role for TGF-β signaling has been 
associated with the induction and maintenance of Foxp3 expression and Treg 
differentiation from the following evidence:  (1) stimulation of Tregs in the presence of 
TGF-β in vitro has been reported to convert CD4
+CD25
-Foxp3
- T cells into 
CD4
+CD25
+Foxp3
+ T cells with suppressive function; and (2) the number of CD4
+CD25
+ T 
cells as well as the level of Foxp3 expression is severely compromised in the periphery of 
TGF-β
-/- and CD4-promoter-dnTGF-β receptor II (TGF-βRII) transgenic mice 
31-33.  
Signalling through the TGF-β receptor has also been reported to confer susceptibility of 
Teffs to Treg-mediated suppression in vivo, as CD4
+CD45RB
high or CD8
+ T cells 
expressing a dominant-negative TGF-βRII were refractory to suppression mediated by 
CD4
+CD25
+ T cells in adoptive transfer models of colitis or diabetes 
34,35.  These data 
indicate that TGF-β signaling tightly controls the differentiation and activation of both 
Tregs and Teffs. 
Previous studies have established that CD4
+ T cells from patients with HAM/TSP are 
resistant to the anti-proliferative effects of TGF-β in vitro, despite the slightly elevated 
levels of TGF-β observed in HAM/TSP patients compared to normal donors 
36,37.  The 
reason underlying this discrepancy remains unknown, although a virus triggered defect in 
the TGF-β signaling pathway remains a possibility.  In the present study, we identify a 
defect in the TGF-β signaling pathway at the level of TGF-βRII expression as well as 
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expression of the TGF-β-inducible gene smad7 in CD4
+ T cells isolated from HAM/TSP 
patients.  Aberrant type II TGF-β receptor expression was observed in both CD4
+CD25
+ 
and CD4
+CD25
- T cells and was associated with disruption of TGF-β-induced Foxp3 
expression, Treg suppressive activity, and susceptibility of Teffs to Treg-mediated 
supression.  Collectively, this study demonstrates that an infectious agent can disrupt both 
Treg and Teff arms of the cellular immune response as a potential contribution to the 
pathogenesis of CNS disease in humans. 
 
METHODS 
Cell culture.  HepG2 cells were cultured in Dulbecco’s modified eagles medium 
(Invitrogen, Carlsbad, CA).  Primary human T cells were cultured in RPMI-1640 medium 
(Invitrogen).  Media were supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 
µg/mL streptomycin (Cambrex, Walkersville, MD), and 10% fetal bovine serum (Atlanta 
Biologicals, Norcross, GA) or 5% human AB serum (Gemini Bio-Products, Woodland, 
CA).  For Foxp3 induction experiments, cells were cultured in X-VIVO 15 (Cambrex). 
Subjects and cell preparation.  PBMC were prepared by centrifugation over Ficoll-
Hypaque gradients (Cambrex) from HAM/TSP patients, and the cells were viably 
cryopreserved in liquid nitrogen until tested.  HAM/TSP was diagnosed according to WHO 
guidelines.  HTLV-I seropositivity was determined by ELISA (Abbott Laboratories, Abbott 
Park, IL), with confirmation by Western blot analysis (Genelabs Technologies, Inc., 
Redwood City, CA).  Blood samples were obtained after informed consent as part of a 
clinical protocol reviewed and approved by the NIH institutional review panel.  A total of 
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12 HAM/TSP patients, 4 HTLV-I-infected asymptomatic carriers, and 18 normal donors 
were utilized in this study. 
Plasmids and siRNA.  Expression vectors encoding HTLV-I Tax and empty control vector 
were a generous gift from Dr. Warner Greene (University of California San Francisco).  A 
synthetic TGF-β-responsive reporter vector p3TP-luc and human TGF-βRII (-1240/+36) 
promoter construct were kindly provided by Dr. Seong-Jin Kim (NCI/NIH).  A human 
Smad7 (-250/+32) promoter construct was provided by Dr. Fang Liu (Rutgers University).  
ON-TARGETplus SMARTpool siRNA reagents targeting GAPDH and Smad4 were 
purchased from Dharmacon (Chicago, IL). 
Isolation of primary human CD4
+, CD4
+CD25
-, and CD4
+CD25
+ T cells.  CD4
+ from 
cryopreserved PBMCs using the Human CD4
+ T cell Isolation Kit II (Miltenyi Biotech, 
Auburn, CA) according to manufacturer’s guidelines.  Purity of negatively selected CD4
+ T 
cells was routinely >97%.  CD4
+CD25
+ (Treg-enriched) and CD4
+CD25
- (Treg-depleted) 
cells were isolated using the Human Regulatory T cell Kit (Miltenyi Biotech) where the 
purity of CD4
+CD25
+ T cells was routinely >94% as determined by flow cytometry. 
Transient expression and luciferase assays.  HepG2 (3.75x10
5 cells/well) cells were 
plated into 6-well culture plates (BD Biosciences, San Diego, CA) one day prior to 
transfection with the appropriate plasmid DNA using FuGene 6 transfection reagent 
(Roche, Indianapolis, IN).  Primary human CD4
+CD25
+ T cells (1x10
6) were nucleofected 
with the specified plasmid DNA or siRNA using the Human T Cell Nucleofection Kit 
(Amaxa, Gaithersburg, MD).  Recombinant human TGF-β (10 ng/mL; R&D Systems, 
Minneapolis, MN) was added in some experiments 4 hrs post transfection.  Twenty-four 
hours post transfection, cells were harvested and luciferase activity was analyzed using the 
Dual-luciferase Reporter Assay System (Promega) and a Monolight 2010 luminometer 
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(Analytical Luminescence Laboratory, San Diego, CA) according to manufacturer’s 
guidelines.  pGL4-TKhRluc2 was used as an internal control to normalize for transfection 
efficiency.  Nucleofected T cells were also monitored for transfection efficiency and cell 
viability 24 hours post transfection as follows.  Transfection efficiency was routinely ~30% 
as determined by flow cytometric analysis of EGFP expression.  Cell viability, determined 
by staining with 7-amino-actinomycin D (7-AAD; BD Biosciences), was routinely ~70%.  
Real-time PCR and RT-PCR (TaqMan).  The HTLV-I proviral DNA load was measured 
as previously described 
16.  Real-time RT-PCR analysis of Foxp3, Smad2, Smad3, Smad4, 
Smad7, TGF-βRII, GAPDH, and HPRT expression was performed using primer and probe 
sets purchased from Applied Biosystems.  Briefly, total RNA was extracted using the 
RNeasy Mini Kit (Qiagen, Valencia, CA) according to manufacturer’s guidelines and 
cDNA was synthesized by reverse transcription using TaqMan Gold RT-PCR Kit reagents 
and random hexamer primers (Applied Biosystems).  Relative quantification of mRNA was 
performed using the comparative threshold cycle method using HPRT as an endogenous 
control.  Relative target gene expression was quantified using an Applied Biosystems 
7900HT FAST Real-Time PCR System.  Where indicated, FAST TaqMan settings were 
used.  For each sample, target gene expression was normalized to the expression of HPRT.  
To determine relative expression levels, the following formula was used:  target gene 
expression = 2
-(Ct[target]-Ct[HPRT]).
 
Flow cytometry.  Cells (1x10
6) were washed once and resuspended in 100 µL FACS 
buffer (1x PBS, 0.05% NaN3, 1% FBS).  Cells were stained for surface CD4  (RPA-T4; BD 
Biosciences) and CD25 (M-A251; BD Biosciences) or the appropriate isotype controls for 
20 min at 4°C.  In some experiments, cells were processed further for intracellular Foxp3 
(236A/E7; eBioscience, San Diego, CA) staining according to the manufacturer’s 
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instructions (eBioscience).  Cells were then acquired on a FACSCalibur (BD Biosciences) 
using CellQuest software (BD Biosciences).  Data analysis was performed using FlowJo 
software (TreeStar, San Diego, CA). 
Proliferation assays.  CD4
+CD25
+ and CD4
+CD25
- T cells (2x10
4 each) from normal 
donors and/or HAM/TSP patients were plated alone or in co-culture into 96-well round-
bottom plates in the presence of soluble anti-CD3 (0.5 µg/mL; HIT3a; BD Biosciences) and 
irradiated accessory cells (5x10
4).  Accessory cells were autologous to the responding cell 
population.  On day 5 of culture, proliferation was analyzed by [
3H]-thymidine 
incorporation during the final 16 hours. 
Foxp3 induction assays.  CD4
+CD25
- T cells (1x10
6) from normal donors or HAM/TSP 
patients were plated in 24-well plates containing IL-2 (100 U/mL), and a combination of 
the following:  plate-bound anti-CD3 (2 µg/mL; UCHT1; BD Biosciences), soluble anti-
CD28 (2 µg/mL; 28.2; BD Biosciences), and rhTGF-β1 (5 ng/mL; Peprotech, Rocky Hill, 
NJ).  On day 5, cells were analyzed for CD25 and Foxp3 expression by flow cytometry. 
Statistical analyses.  Analysis of variance and the Mann-Whitney test was used to compare 
the data between patients with HAM/TSP, asymptomatic carriers, and normal donors.   
Analysis of variance and the unpaired t test was used to compare changes 3TP-luc, Smad7-
luc, and TGF-βRII-luc activity caused by overexpression of HTLV-I Tax.  Linear 
regression analysis was used to test the correlation between HTLV-I tax proviral load in 
PBMC, TGF-βRII mRNA in CD4
+ T cells, and % CD25
+Foxp3
+ T cell induction.   
Statistical analyses were performed using Prism (GraphPad Software, San Diego, CA). 
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RESULTS 
Blockade of TGF-β signaling by HTLV-I Tax and in patients with HAM/TSP.  HTLV-
I Tax has been implicated in the pathogenesis of HAM/TSP through stimulation of T cell 
activation and cytokine production, altering cell signalling pathways, and acting as an 
antigen for virus-specific CD4
+ and CD8
+ T cells 
38.  Previous studies have shown that the 
HTLV-I Tax protein inhibits cell signaling through the TGF-β pathway, although the 
precise mechanism remains controversial 
39-41.  A schematic diagram of the TGF-β 
signaling pathway is shown in Figure 1A.  In this study, we confirmed the ability of Tax to 
inhibit TGF-β-dependent gene expression by analyzing the activation of a synthetic 
reporter (3TP-luc) or a Smad7 promoter luciferase reporter construct (Smad7-luc), each 
containing Smad3/4 binding sites and each responsive to TGF-β.  The smad7 gene is a 
target of TGF-β that functions in a dominant-negative manner to block subsequent TGF-β 
signaling, and to suppress NF-κB activation and inflammatory cytokine production 
42-45.  
Transcription from both 3TP-luc (Figure 1B) and Smad7-luc (Figure 1C) reporters were 
stimulated by addition of TGF-β to HepG2 cells.  Overexpression of HTLV-I Tax, 
however, dramatically suppressed the effects of TGF-β.  Together, this evidence suggests 
that expression of Foxp3 and TGF-β-inducible genes (e.g., smad7) are both inhibited by 
Tax.  Moreover, previous studies have demonstrated that Foxp3 is a TGF-β-inducible gene 
itself 
31. 
Since Tax can disrupt TGF-β signaling in vitro, we next asked whether the TGF-β 
signaling pathway was affected in patients with HAM/TSP.  To address this question, we 
examined purified CD4
+ T cells (which represent a primary target of HTLV-I) from ten 
normal donors, three HTLV-I-infected asymptomatic carriers, and ten HAM/TSP patients 
using magnetic bead separation and analyzed the expression of an endogenous TGF-β-
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responsive gene (smad7) by real-time RT-PCR.  These studies revealed that Smad7 
expression was significantly reduced in both asymptomatic carriers and HAM/TSP patients 
compared to normal donors (Figure 1D).  This reduction was not the result of aberrant 
expression of Smad3 (Figure 1E) or Smad4 (Figure 1F), key effector molecules in the TGF-
β signaling pathway whose expression has been reported to be unaffected by Tax 
39.  These 
data suggest that the expression of TGF-β-responsive genes are inhibited during HTLV-I 
infection, most likely through the effects of Tax expressed in infected CD4
+ T cells.  To 
determine whether other steps in the TGF-β signaling pathway were altered in HTLV-I-
infected individuals, the expression of TGF-βRII in CD4
+ T cells was examined.  Our 
analysis revealed that TGF-βRII mRNA levels were significantly reduced in HAM/TSP 
patients, compared to normal donors (Figure 1G).  A similar deficiency in TGF-βRII 
expression in HTLV-I-infected lymphocytes compared to activated normal donor 
lymphocytes has previously been reported by Brady and colleagues 
46.  The reduction of 
TGF-βRII expression in HAM/TSP patients was likely the direct result of Tax expression 
within infected CD4
+ T cells, since overexpression of Tax down-regulated the 
transcriptional activation of the TGF-βRII promoter (Figure 1H).  Collectively, this 
evidence suggests the presence of a TGF-β signaling defect in patients with HAM/TSP 
caused by the HTLV-I transactivating gene tax. 
We have previously demonstrated an inverse correlation between Foxp3 expression 
and the HTLV-I tax proviral load 
47.  Since TGF-β signaling has been reported to play a 
critical role in stimulating Foxp3 expression 
31,48, we hypothesized that if reduced TGF-
βRII levels were causing the loss of Foxp3 expression in HTLV-I-infected individuals, that 
TGF-βRII expression would also inversely correlate with the HTLV-I tax proviral load.  To 
test this hypothesis, we plotted the levels of TGF-βRII expression in CD4
+ T cells against 
the HTLV-I tax proviral load in PBMC of HTLV-I-infected individuals.  Indeed, a 
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significant inverse correlation was found between the levels of TGF-βRII expression and 
the HTLV-I tax proviral load from ten HTLV-I-infected individuals (P=0.0216, R
2=0.50, 
linear regression analysis, Figure 1I) suggesting that dysregulation of TGF-β signaling is 
involved in the pathogenesis of HAM/TSP, likely through silencing of downstream TGF-β-
responsive genes, including foxp3. 
Smad3/4 play a role in regulating Foxp3 expression.  Fantini and colleagues and Tran 
and colleagues have previously reported that Foxp3 expression can be induced in 
CD4
+CD25
- T cells by stimulating in the presence of TGF-β 
31,48.  Additional studies have 
demonstrated that TGF-β
-/- mice or CD4-promoter dnTGF-βRII transgenic mice develop 
lethal autoimmunity and exhibit reduced peripheral CD4
+CD25
+Foxp3
+ T cells and loss of 
suppressor function 
32,33.  These reports suggest that TGF-β signalling is critical for the 
induction and maintenance of Foxp3 expression in the periphery and that a defect in TGF-β 
signaling could precipitate a decrease in Foxp3 expression and loss of suppressor function 
in Tregs.  Therefore, if TGF-β/Smad signaling is important for Foxp3 expression in human 
CD4
+CD25
+ T cells, then a defect in this pathway could be the mechanism for the reduction 
in Foxp3 expression observed in patients with HAM/TSP.  To examine whether TGF-β 
signaling plays a role in directing Foxp3 expression in human CD4
+CD25
+ T cells, we 
introduced siRNA molecules (a pre-designed pool of four siRNA species) specific for 
either Smad4 or, as an irrelevant control, GAPDH and assayed endogenous Foxp3 
expression after 24 hours by FAST real-time RT-PCR (FAST TaqMan).  GAPDH and 
Smad4 expression was examined in parallel for siRNA knock-down efficiency.  The results 
from four independent experiments using different normal donors are shown in Figure 2A 
and demonstrate that Smad4 siRNA caused a reduction in Foxp3 mRNA in CD4
+CD25
+ T 
cells compared to CD4
+CD25
+ T cells transfected with control siRNA.  To demonstrate the 
specificity of the Smad4 siRNA, CD4
+ T cells from four normal donors were transfected 
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with siRNA to Smad4 or GAPDH and assayed for Smad2, Smad3, and Smad4 expression 
after 24 hours.  The results in Figure 2B indicated that Smad4 siRNA only affected the 
expression of Smad4 and not Smad transcription factor family members Smad2 or Smad3. 
These results point to Smad4 playing a potentially important role in regulating Foxp3 
expression.  Analysis of the human Foxp3 promoter for transcription factor binding sites 
using Genomatrix MatInspector database yielded a number of putative Smad3/4 binding 
sites (Figure 2C).  Future studies will be able to examine in detail the potential interactions 
between Smad3/4 and the Foxp3 promoter region and the functional consequences of such 
interactions. 
Reduced TGF-βRII expression in both CD4
+CD25
+ and CD4
+CD25
- T cells is 
associated with a functional defect in regulatory and effector T cell populations in 
patients with HAM/TSP.  Although TGF-β-mediated signaling has been recognized as 
playing a role in inducing and maintaining Foxp3 expression and Treg suppressor function, 
previous reports also suggest that a TGF-β signaling defect in the Teff population may 
render these cells unresponsive to Treg-mediated suppression 
34,35.  To investigate whether 
the TGF-βRII defect observed in CD4
+ T cells in HAM/TSP patients translated into a 
defect in Treg and/or Teff populations, we isolated CD4
+CD25
+ and CD4
+CD25
- T cells 
from normal donors and HAM/TSP patients by magnetic bead separation and assessed the 
expression of TGF-βRII in both populations.  As shown in Figure 3A, the expression of 
TGF-βRII was consistently greater in CD4
+CD25
- T cells compared to CD4
+CD25
+ T cells 
in both normal donors and HAM/TSP patients.  In addition, the expression of TGF-βRII 
was lower in both CD4
+CD25
+ and CD4
+CD25
- T cell populations from HAM/TSP 
patients compared to the same populations in normal donors. 
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Since the data in Figure 1I suggests that loss of TGF-βRII expression was associated 
with the pathogenesis of HAM/TSP, we investigated whether reduced TGF-βRII 
expression in CD4
+CD25
+ and CD4
+CD25
- T cells from patients HAM/TSP would 
adversely impact TGF-β-induced Foxp3 expression and/or Treg and Teff function.  We 
first examined the ability of CD4
+CD25
-Foxp3
- T cells from HAM/TSP patients to convert 
to CD4
+CD25
+Foxp3
+ T cells in the presence of TGF-β.  CD4
+CD25
-Foxp3
- T cells from 
five patients with HAM/TSP were stimulated with anti-CD3 and anti-CD28 antibodies in 
the presence of TGF-β in serum-free media.  CD25 and Foxp3 expression was analyzed 
five days later by flow cytometry.  The results from these experiments were plotted against 
the HTLV-I tax proviral load of each HAM/TSP patient (Figure 3B).  Conversion of 
CD4
+CD25
-Foxp3
- T cells into CD4
+CD25
+Foxp3
+ T cells exhibited a significant inverse 
correlation with the HTLV-I tax proviral load as determined by real-time PCR (P=0.0331, 
R
2=0.82, linear regression analysis).  These results indicate that the ability of TGF-β to 
induce Foxp3 expression in HAM/TSP patients was repressed as a function of disease 
progression. 
Next we preformed co-culture proliferation assays using CD4
+CD25
+ and CD4
+CD25
- 
T cells from normal donors and HAM/TSP patients to specifically test the ability of Tregs 
to suppress Teff proliferation as well as the susceptibility of Teffs to Treg-mediated control.  
We hypothesized that, as previously reported in murine systems 
33,34, inhibition of TGF-
βRII expression (as a result of HTLV-I infection) would lead to loss of Treg suppression of 
Teff proliferation as well as resistance of Teffs to Treg-mediated control.   The results from 
this set of experiments are shown in Figure 3C (two of three independent experiments are 
shown using a different normal donor and HAM/TSP patient in each experiment).   
CD4
+CD25
+ T cells from normal donors were hyporesponsive to stimulation with anti-
CD3, whereas CD4
+CD25
- T cells from normal donors proliferated robustly under identical 
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conditions.  When co-cultured at a 1:1 ratio, normal donor CD4
+CD25
+ T cells suppressed 
the proliferation of normal donor CD4
+CD25
- T cells.  HAM/TSP CD4
+CD25
+ T cells were 
less hyporesponsive to stimulation with anti-CD3 in comparison to normal donor 
CD4
+CD25
+ T cells.  HAM/TSP CD4
+CD25
+ T cells failed to suppress the proliferation of 
normal donor CD4
+CD25
- T cells when co-cultured together in a 1:1 ratio, indicating a 
defect in the ability of HAM/TSP CD4
+CD25
+ T cells to suppress the proliferation of 
normal donor CD4
+CD25
- T cells (as previously reported 
29).  Finally, CD4
+CD25
+ T cells 
from normal donors failed to suppress the proliferation HAM/TSP CD4
+CD25
- T cells 
when co-cultured together in a 1:1 ratio.  These data suggest HAM/TSP CD4
+CD25
- T cells 
remain refractory to Treg-mediated suppression.  In conclusion, both Treg and Teff 
populations exhibit a profound functional deficit in patients with HAM/TSP due to virus-
induced down-regulation of TGF-βRII.   Future studies are required to determine the full 
implications that dysregulation of TGF-β signaling has on Treg and Teff function observed 
in HTLV-I-induced neuroinflammatory disease. 
 
DISCUSSION 
TGF-β signaling plays a critical role in immune tolerance, not only by maintaining 
Foxp3 expression in peripheral Tregs, but also by promoting Teff susceptibility to Treg-
mediated suppression.  Evidence presented herein point to a defect in TGF-β signaling as a 
result of infection with a human retrovirus.  As observed in mice with engineered blocks in 
TGF-β signaling, patients with HAM/TSP exhibit a chronic inflammatory disorder 
characterized by accumulation of activated CD4
+ and CD8
+ T cells 
16,32,33,49.  CD4
+CD25
+ 
T cells from HAM/TSP patients also exhibit an activated phenotype marked by decreased 
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expression of CD45RA together with increased expression of IL-2 and IFN-γ compared to 
CD4
+CD25
+ T cells from healthy individuals 
29.  CD4
+CD25
+ T cells represent the 
predominant viral reservoir in the peripheral blood in patients with HAM/TSP 
21.  
Therefore persistent T cell activation in patients with HAM/TSP triggered by viral antigens 
such as Tax together with down-regulation of Foxp3 may result in decline of the 
CD4
+CD25
+Foxp3
+ Treg population and accumulation of CD4
+CD25
+Foxp3
- T cells that 
lack suppressive function, but are capable of exacerbating the disease process (see Figure 
4). 
HTLV-I Tax is a multi-functional protein known for its ability to activate or silence 
the transcription of cellular genes in trans (reviewed in 
50). We have demonstrated that Tax 
inhibited expression of both endogenous Foxp3 (previously reported 
29) and transcriptional 
activation of the Smad7 and TGF-βRII promoters.  The expression of these genes was 
significantly reduced in HAM/TSP patients, and TGF-βRII expression as well as induction 
of Foxp3 negatively correlated with the HTLV-I tax proviral load.  This evidence suggests 
that virus-induced dysregulation of TGF-β signaling prevents the expression of TGF-β 
target genes (e.g., Foxp3).  Although TGF-β signaling has been implicated in this study as 
playing an important role in regulating Foxp3 expression, it is possible that HTLV-I Tax 
may also impact Foxp3 transcription by interacting with and disrupting additional signaling 
pathways.  For example, IL-2 and STAT5b have also been reported to play an essential role 
for inducting Foxp3 expression 
51,52.  Therefore, disruption of either of these signaling 
pathways could also lead to inhibition of Foxp3 expression and loss of Treg function during 
HTLV-I pathogenesis.  However, much evidence exists to argue against this possibility.  
Both IL-2 and the IL-2Rα (CD25) are up-regulated in patients with HAM/TSP 
53.  In 
addition, the transactivating HTLV-I tax gene induces STAT5 mRNA and protein 
expression, while another viral protein, HTLV-I p12
I, enhances STAT5b DNA binding 
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activity and STAT5b-mediated transcriptional activation 
54,55.  A recent study has reported 
that patients that harbour a loss of function mutation in STAT5b were reported to exhibit 
reduced CD25 expression compared to controls, while CD25 is up-regulated in patients 
with HAM/TSP compared to healthy controls 
52,53.  STAT5b-mutant CD4
+CD25
+ T cells 
exhibited a loss of suppressor function, similar to what we reported herein for CD4
+CD25
+ 
T cells from patients with HAM/TSP.  However, proliferation of STAT5b-mutant 
CD4
+CD25
- T cells was able to be suppressed by Tregs from controls patients 
52, whereas 
CD4
+CD25
- T cells from HAM/TSP patients remained refractory to suppression mediated 
by CD4
+CD25
+ T cells from normal donors.  Collectively, the situation in HAM/TSP 
patients does not resemble that of patients harbouring a loss of function mutation in 
STAT5b, but rather the situation reported in murine systems with engineered blocks in 
TGF-β signaling.  In addition to the evidence presented herein indicating that TGF-β 
signaling is important for Foxp3 expression in Tregs as well as inducible Foxp3 expression 
in Teffs, a recent study has reported that Tregs block the polarization of antigen-specific T 
cells towards antigen-presenting cells in a TGF-β-dependent manner 
56. 
Defects in Foxp3 expression and/or Treg function have been reported in a number of 
human autoimmune diseases 
26-28.  HAM/TSP is a virus-induced neuroinflammatory 
disorder in which the expression of Foxp3 and the function of Tregs have been found 
deficient 
29.  Hafler and colleagues demonstrated in co-culture proliferation assays that 
Tregs isolated from MS patients were unable to suppress Teffs derived from either MS 
patients or healthy donors.  However, Teffs from MS patients remained susceptible to 
suppression mediated by Tregs isolated from healthy individuals 
26.  This evidence suggests 
that the defect in Treg function in patients with MS reflects an inability of Tregs to suppress 
proliferation of Teffs rather than the Teff population being refractory to Treg-mediated 
control.  Although Tregs from HAM/TSP were shown in this study to also lack suppressive 
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function, unlike MS, Tregs derived from normal donors could not control the proliferation 
of Teffs from HAM/TSP patients.  This evidence points to a two-fold defect in 
immunological tolerance in patients with HAM/TSP:  (1) loss of suppressive function in 
CD4
+CD25
+ T cells; and (2) escape of CD4
+CD25
- T cells from Treg-mediated control.  In 
this study, both TGF-βRII expression and CD4
+CD25
+Foxp3
+ T cell induction inversely 
correlated with the HTLV-I tax proviral load in HTLV-I-infected individuals, suggesting 
that disruption of TGF-β signaling may be a co-factor in the progression of HAM/TSP.  
Evidence in support of this hypothesis has been reported by Powrie and colleagues, which 
demonstrated using an adoptive transfer model of autoimmunity that TGF-βRII expression 
on both regulatory and effector T cell populations is critical for maintaining a check on the 
expansion of potentially pathogenic T cells 
34.  A role for dysregulated TGF-β signaling in 
the pathogenesis of inflammatory bowel disease and Alzheimer’s disease has also been 
recently reported 
57,58, reiterating the importance of this pathway in protecting against 
chronic inflammatory disease.   
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FIGURE LEGENDS 
Figure 1.  Suppression of TGF-β signaling in vitro by HTLV-I Tax and in HTLV-I-
infected patients.  (A) Schematic diagram of the TGF-β signalling pathway.  HepG2 cells 
were transfected with either a (B) synthetic TGF-β/Smad reporter vector (3TP-luc), (C) 
Smad7 promoter construct, or (H) TGF-βRII promoter construct in combination with the 
indicated expression vectors and/or rhTGF-β1.  After 24 hours, cell lysates were assayed 
for luciferase activity.  Total RNA from CD4
+ T cells from ten normal donors (ND), three 
HTLV-I-infected asymptomatic carriers (AC), and ten patients with HAM/TSP were 
assayed for endogenous (D) Smad7, (E) Smad3, (F) Smad4, or (G) TGF-βRII mRNA 
expression by real-time RT-PCR (TaqMan).  (I) A statistically significant negative 
correlation (P=0.0216, R
2=0.50) between the HTLV-I tax proviral load in PBMC and the 
TGF-βRII mRNA expression in CD4
+ T cells was observed in HTLV-I-infected patients. 
Figure 2.  A role for Smad3/4 in the expression of Foxp3 in CD4
+CD25
+ T cells.  (A) 
CD4
+CD25
+ T cells from normal donors were transfected with the indicated siRNA and 
assayed for Foxp3 mRNA expression after 24 hours by FAST real-time RT-PCR (FAST 
TaqMan).  GAPDH and Smad4 mRNA expression was also analyzed in parallel to monitor 
siRNA-mediated knock-down efficiency.  Shown are results from four independent 
experiments using a different donor for each experiment.  (B) To demonstrate Smad4 
siRNA specificity, CD4
+ T cells from four normal donors were transfected with Smad4 
siRNA or GAPDH siRNA (irrelevant control) and assayed for Smad2, Smad3, and Smad4 
expression by FAST real-time RT-PCR (FAST TaqMan).  (C) Schematic representation of 
the human Foxp3 promoter regions with putative transcription factor binding sites. 
Figure 3.  Dysregulation of TGF-βRII expression and loss of regulatory and effector T 
cell function in patients with HAM/TSP.  (A) CD4
+CD25
+ and CD4
+CD25
- T cells from 
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two normal donors and two patients with HAM/TSP were analyzed for TGF-βRII mRNA 
expression by real-time RT-PCR (TaqMan).  (B) CD4
+CD25
-Foxp3
- T cells from 
HAM/TSP patients (n = 5) were cultured for 5 days in the presence of a combination of the 
following:  plate-bound anti-CD3 monoclonal antibody, soluble anti-CD28 monoclonal 
antibody, rhTGF-β1, and rhIL-2.  On day 5, cells were analyzed for conversion into 
CD4
+CD25
+Foxp3
+ T cells by flow cytometry.  A statistically significant inverse 
correlation between the % CD25
+Foxp3
+ T cell induction and the HTLV-I tax proviral load 
was observed in PBMC from patients with HAM/TSP.  (C) CD4
+CD25
+ and CD4
+CD25
- T 
cells from normal donors or patients with HAM/TSP were cultured separately or in co-
culture in the presence or anti-CD3 monoclonal antibody and irradiated accessory cells for 
5 days.  Proliferation was analyzed by [
3H]-thymidine incorporation during the final 16 
hours.  Shown are the results of two independent experiments pairing a different normal 
donor and HAM/TSP patient in each experiment. 
Figure 4.  Loss of immune tolerance caused by HTLV-I Tax.  In healthy individuals, 
CD4
+CD25
+Foxp3
+ Tregs suppress the proliferation of Teffs through (1) constitutive 
expression of Foxp3, and (2) induction of Foxp3 expression in Teffs (also known to as 
infectious tolerance).  However, in patients with HAM/TSP, HTLV-I Tax down-regulates 
TGF-βRII, which silences TGF-β-responsive genes such as foxp3.  The resulting block in 
Foxp3 expression causes Tregs to lose suppressor function and causes Teffs to become 
resistant to TGF-β-inducible Foxp3 expression.  The result is a breakdown in immune 
tolerance in patients with HAM/TSP characterized by expansion of potentially pathogenic 
CD4
+ and CD8
+ T cells and production of pro-inflammatory cytokines. 
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